ICIs	immune checkpoint inhibitors
CTLA-4	cytotoxic T lymphocyte antigen-4
PD-1	programmed cell death protein 1
FDA	the US food and drug administration
NSCLS	non-small cell lung cancer
SCLS	small cell lung cancer
RCC	renal cell carcinoma
HNC	head and neck cancer
UC	urothelial carcinoma
CRC	colorectal cancer
ORR	overall response rate
TKIs	tyrosine kinase inhibitors
STRs	short tandem repeats
MSI	microsatellite instability
MMR	mismatch repair
LD-SCLC	limited disease SCLC
ED-SCLC	extensive-disease SCLC
OS	overall survival
MDSCs	myeloid-derived suppressor cells
EC	esophageal cancer
HCC	hepatocellular carcinoma
MTD	maximum tolerated dose
CR	complete response
PR	partial response
mPFS	median progression-free survival
HNC	head and neck cancer
UC	urothelial carcinoma
UBC	urinary bladder cancer
UTUC	upper tract urothelial carcinoma
irAEs	immune-related adverse effects